|   | |
| Clinical data | |
|---|---|
| Other names | N,N-dimethyl-8-chloro-5-methoxy-1-aminotetralin | 
| ATC code | 
 | 
| Identifiers | |
| 
 | |
| CAS Number | 
 | 
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C13H18ClNO | 
| Molar mass | 239.74 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
Lometraline (INN; developmental code name CP-14,368) is a drug and an aminotetralin derivative. [1] A structural modification of tricyclic neuroleptics, lometraline was originally patented by Pfizer as an antipsychotic, tranquilizer, and antiparkinsonian agent. [2] [3] However, it was instead later studied as a potential antidepressant and/or anxiolytic agent, though clinical studies revealed no psychoactivity at the doses used and further investigation was suspended. [1] [4] [5] Further experimental modifications of the chemical structure of lometraline resulted in the discovery of tametraline, a potent inhibitor of the reuptake of dopamine and norepinephrine, which in turn led to the discovery of the antidepressant sertraline, a selective serotonin reuptake inhibitor (SSRI). [6]